Optimize your treatment of endometriosis by using an FDA-approved hormonal medication

Robert L. Barbieri
In: OBG Management · 2021 · vol. 33(4) · doi:10.12788/obgm.0084 · W3201113669
article OA: bronze CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

If an initial estrogen-progestin contraceptive fails to alleviate endometriosis pain, switch to an FDA-approved treatment specifically for endometriosis-associated pelvic pain instead of a different brand of the same contraceptive type.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 ⓘ

This editorial discusses optimizing hormonal management of endometriosis-related pelvic pain, focusing on what to do when a patient has suboptimal pain control on an estrogen–progestin contraceptive. The author summarizes FDA-approved hormone options and reports findings from cohort studies and clinical trials, including that norethindrone acetate (NEA) improved pelvic pain in large cohorts (e.g., 65% significant improvement in one study) but was associated with side effects such as weight gain and breakthrough bleeding, while elagolix reduced dysmenorrhea and nonmenstrual pain versus placebo and showed bone density changes and vasomotor symptoms depending on dose. A key limitation highlighted is that some NEA evidence is based on cohort studies rather than large controlled trials, and the editorial is based on the author’s clinical experience rather than a new systematic study. This paper is centrally about endometriosis — it provides an evidence- and FDA-guided overview of switching hormonal therapies when pelvic pain is inadequately controlled.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

For women with endometriosis, if one estrogen-progestin contraceptive results in suboptimal control of pelvic pain, do not prescribe a different brand of the same contraceptive type. In this situation, prescribe one of the US Food and Drug Administration (FDA) approved treatments for pelvic pain caused by endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK